Physician profile
John J Upegui
NPI 1811272990
$1,310.53
in general payments reported to CMS, 2019-2025
23 companies · $624 in 2025
The $624 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $29.80 · 2023: $20.27 · 2024: $323 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $225.46 | 2021-2025 | |
| Novo Nordisk INC | $142.57 | 2024-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $133.87 | 2024-2025 | Breztri, Lokelma |
| Scilex Pharmaceuticals INC. | $92.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.55 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $75.39 | 2024-2025 | |
| Redhill Biopharma INC. | $69.01 | 2021 | |
| Lundbeck LLC | $66.31 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $59.78 | 2024-2025 | Nuzyra |
| Pfizer INC. | $56.06 | 2025 | |
| Exact Sciences Corporation | $45.37 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $30.13 | 2024 | Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $29.98 | 2025 | Rexulti |
| Astellas Pharma US INC | $27.81 | 2025 | Veozah |
| Pharmacosmos Therapeutics INC. | $25.45 | 2025 | Monoferric |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.36 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Madrigal Pharmaceuticals | $22.71 | 2025 | Rezdiffra |
| Forte Bio-Pharma LLC | $21.29 | 2021 | |
| Lilly USA, LLC | $19.31 | 2024 | Zepbound |
| Sanofi-Aventis U.S. LLC | $18.28 | 2024 | |
| Virtus Pharmaceuticals LLC | $17.58 | 2021 | |
| Hikma Pharmaceuticals USA | $15.62 | 2022 | |
| Neurocrine Biosciences, INC. | $14.78 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Upegui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.